Successsful voriconazole treatment of disseminated Fusarium infection in an immunocompromised patient

Clinical Infectious Diseases

Volumn 37, Issue 2, 2003, Pages 311-313

  Consigny, Sophie ^a   Dhedin, Nathalie ^a   Datry, Annick ^a   Choquet, Sylvain ^a   Leblond, Véronique ^a   Chosidow, Olivier ^a,b  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; CYTARABINE; DOXORUBICIN; NITROSOUREA; VORICONAZOLE; ANTIFUNGAL AGENT; PYRIMIDINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; FUSARIUM; HUMAN; IMMUNE DEFICIENCY; MALE; MORBIDITY; MORTALITY; MYCOSIS; NEUTROPENIA; PRIORITY JOURNAL; SKIN INFECTION; SKIN MANIFESTATION; TREATMENT OUTCOME; TREATMENT PLANNING; DISEASE TRANSMISSION; DRUG EFFECT; PATHOPHYSIOLOGY;

AGED; AMPHOTERICIN B; ANTIFUNGAL AGENTS; FUSARIUM; HUMANS; IMMUNOCOMPROMISED HOST; MALE; MYCOSES; NEUTROPENIA; PYRIMIDINES; TREATMENT OUTCOME; TRIAZOLES;

EID: 0042768560     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/375842     Document Type: Article

References (19)

1. Musa OM, Al Eisa A, Halim M, et al. The spectrum of Fusarium infection in immunocompromised patients with haematological malignancies and in non-immunocompromised patients: a single institution experience over 10 years. Br J Haematol 2000; 108:544-8.
2. Boutati EI, Anaissie EJ. Fusarium, a significant emerging pathogen in patients with haematologic malignancy: ten years' experience at a cancer center and implications for management. Blood 1997; 90:999-1008.
3. Hennequin C, Lavarde V, Poirot JL, et al. Invasive fusarium infections: a retrospective survey of 31 cases. J Med Vet Mycol 1997; 35:107-14.
4. Clancy CJ, Nguyen MH. In vitro efficacy and antifungicidal activity of voriconazole against Aspergillus and Fusarium species. Eur J Clin Microbiol Infect Dis 1998; 17:573-5.
5. Segal BH, Walsh TJ, Liu JM, Wilson JD, Kwon-Chung KJ. Invasive infection with Fusarium chlamydosporum in a patient with aplastic anemia. J Clin Microbiol 1998; 36:1772-6.
6. Nucci M, Anaissie E. Cutaneous infection by Fusarium species in healthy and immunocompromised hosts: implications for diagnosis and management. Clin Infect Dis 2002; 35:909-20.
7. Perfect JR, Lutsar I, Gonzalex-Ruiz A. Voriconazole for the treatment of resistant and rare fungal pathogens [abstract 303]. In: Program and Abstracts of the 38th Annual Meeting of the Infectious Diseases Society of America (New Orleans). 2000.
8. Reis A, Sundmacher R, Tintelnot K, Agostini H, Jensen HE, Althaus C. Successful treatment of an ocular invasive mould infection (fusariosis) with the new antifungal agent voriconazole. Br J Ophthalmol 2000; 84:932-3.
9. Pujol I, Guarro J, Gene J, Sala J. In-vitro antifungal susceptibility of clinical and environmental Fusarium spp. Strains. J Antimicrob Chemother 1997; 39:163-7.
10. Clancy CJ, Hong Nguyen M. The combination of amphotericin B and azithromycin as a potential new therapeutic approach to fusariosis. J Antimicrob Chemother 1998; 41:127-30.
11. Espinel-Ingroff A, Boye K, Sheehan DJ. In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature. Mycopathologia 2001; 150:101-15.
12. Sabo JA, Abdel-Rahman SM. Voriconazole: a new triazole antifungal. Ann Pharmacother 2000; 34:1032-43.
13. Guarro J, Pujol I, Mayayo E. In vitro and in vivo experimental activities of antifungal agents against Fusarium solani. Antimicrob Agents Chemother 1999; 43:1256-7.
14. Chandrasekar PH, Manavathu E. Voriconazole: a second-generation triazole. Drugs Today Barc 2001; 37:135-48.
15. Herbrecht R, Denning DW, Paterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347:408-15.
16. Ally R, Schurmann D, Kreisel W, et al. A randomized, double-blind, double-dummy, multitrial of vorlconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 2001; 33:1447-54.
17. Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346:225-34.
18. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Reviews of anti-infective agents. Clin Infect Dis 2003; 36:630-7.
19. Ghannoum MA, Kuhn DM. Voriconazole: better chances for patients with invasive mycoses. Eur J Med Res 2002; 7:242-56.